NIH Dementia Care Summit

Evolving Dementia Landscape

Dementia care has surged to the forefront of public health concerns as populations age rapidly. In 2025, nearly 7.2 million Americans lived with Alzheimer's disease, a number projected to double by 2050. Recent FDA approvals of monoclonal antibody treatments, such as lecanemab in 2023 and donanemab in 2024, mark a pivotal shift. These drugs target amyloid plaques in the brain, slowing cognitive decline in early stages. Yet, their high costs—often exceeding $26,000 annually—and limited efficacy underscore the need for robust support systems beyond pharmaceuticals.

The economic toll is staggering. Total payments for health care, long-term care, and hospice services for those over 65 with dementia hit $384 billion in 2025. This figure excludes the unquantified emotional and financial strain on family caregivers, who provide billions of hours of unpaid labor each year. Workforce shortages in long-term care facilities compound the issue, with providers struggling to retain staff amid low wages and high burnout rates. Innovative models, like those promoted by the Alzheimer's Association's new white paper, aim to build business cases for integrated dementia programs, but adoption remains uneven.

Stakeholders face concrete deadlines. The Advisory Council on Alzheimer's Research, Care, and Services is updating the National Plan for 2026-2035, incorporating insights from summits like the one scheduled for March 2026. Failure to act risks escalating costs and poorer outcomes, including a 12 percent higher hospitalization rate for dementia patients without adequate community support. Risks of inaction include widened health disparities; for instance, Black and Hispanic Americans experience dementia at rates 1.5 to 2 times higher than whites, yet face barriers to diagnosis and treatment.

Non-obvious tensions emerge in balancing innovation with equity. While lifestyle interventions from trials like U.S. POINTER—emphasizing diet, exercise, and cognitive training—show promise in reducing risk by up to 20 percent, they require resources not always available in low-income areas. Trade-offs in policy involve prioritizing research funding for biomarkers and early detection versus expanding caregiver training programs. Surprising data from 2025 studies reveal that structured behavioral management can improve quality of life more than expected, challenging the drug-centric approach.